ANDA 211622, held by Lannett Co Inc. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 211622 (Solifenacin Succinate), held by Lannett Co Inc, was first approved by FDA on Jun 6, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 6, 2023 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Discontinued |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters